Limits...
Urinary Angiotensinogen Could Be a Prognostic Marker of Renoprotective Effects of Alogliptin in Patients with Type 2 Diabetes.

Mizushige T, Kobori H, Nishijima Y, Yano Y, Sakata K, Hayakawa M, Nishiyama A - J Diabetes Res (2015)

Bottom Line: Alogliptin treatment tended to decrease UAlbCR (99.6 ± 26.8 versus 114.6 ± 36.0 mg/g Cr, P = 0.198).When all patients were redivided into two groups, those with higher values of UAGTCR before the treatment (Group H, n = 20) and those with lower values (Group L), Group H showed significantly decreased UAlbCR in response to alogliptin (-14.6 ± 8.6 versus +22.8 ± 16.8%, P = 0.033).Urinary AGT could be a prognostic marker of renoprotective effects of alogliptin in patients with T2D.

View Article: PubMed Central - PubMed

Affiliation: Kagawa University School of Medicine, Kagawa 761-0793, Japan ; Jichi Medical University School of Medicine, Tochigi, Japan.

ABSTRACT

Background: The aims of this study were (1) to examine the renoprotective effects of alogliptin and (2) to establish urinary angiotensinogen (AGT) as a prognostic marker of renoprotective effects of alogliptin in patients with type 2 diabetes (T2D).

Methods: In 43 patients with T2D (18 women, 66.1 ± 1.71 years), 25 mg/day of alogliptin was added to the traditional hypoglycemic agents and/or nondrug treatments. Urinary concentrations of albumin (Alb) and AGT, normalized by urinary concentrations of creatinine (Cr) (UAlbCR and UAGTCR, respectively), were measured before and after the 12-week alogliptin treatment.

Results: Alogliptin treatment tended to decrease UAlbCR (99.6 ± 26.8 versus 114.6 ± 36.0 mg/g Cr, P = 0.198). Based on % change in UAlbCR, patients were divided into two groups, responders (< -25%) and nonresponders (≥ -25%), and a logistic analysis of UAGTCR before treatment showed cutoff value of 20.8 µg/g Cr. When all patients were redivided into two groups, those with higher values of UAGTCR before the treatment (Group H, n = 20) and those with lower values (Group L), Group H showed significantly decreased UAlbCR in response to alogliptin (-14.6 ± 8.6 versus +22.8 ± 16.8%, P = 0.033).

Conclusion: Urinary AGT could be a prognostic marker of renoprotective effects of alogliptin in patients with T2D.

No MeSH data available.


Related in: MedlinePlus

ΔUrinary concentrations of Alb normalized by urinary concentrations of creatinine (UAlbCR) defined by the cutoff value of urinary concentrations of angiotensinogen normalized by urinary concentrations of creatinine (UAGTCR) before treatment. When all patients were redivided into two groups, those with higher UAGTCR levels before treatment (Group H, n = 20) and those with lower levels (Group L), ΔUAlbCR was significantly lower in Group H than in Group L (−46.3 ± 32.5 versus +12.2 ± 14.9 mg/g Cr, P = 0.0474).
© Copyright Policy - open-access
Related In: Results  -  Collection


getmorefigures.php?uid=PMC4562181&req=5

fig3: ΔUrinary concentrations of Alb normalized by urinary concentrations of creatinine (UAlbCR) defined by the cutoff value of urinary concentrations of angiotensinogen normalized by urinary concentrations of creatinine (UAGTCR) before treatment. When all patients were redivided into two groups, those with higher UAGTCR levels before treatment (Group H, n = 20) and those with lower levels (Group L), ΔUAlbCR was significantly lower in Group H than in Group L (−46.3 ± 32.5 versus +12.2 ± 14.9 mg/g Cr, P = 0.0474).

Mentions: Based on this cutoff value of UAGTCR (i.e., ≥20.8 μg/g Cr or <20.8 μg/g Cr), we divided all patients into 2 groups: higher (Group H, n = 20) and lower (Group L) values of UAGTCR at baseline. Clinical characteristics (Table 3) and baseline laboratory data (gender, age, BMI, treatment duration of T2D, HbA1c (NGSP), eGFR, SBP, DBP, and medications) (Table 4) were not significantly different between Group H and Group L. However, ΔUAlbCR was significantly lower in Group H than in Group L (−46.3 ± 32.5 versus +12.2 ± 14.9 mg/g Cr, P = 0.0474, Figure 3).


Urinary Angiotensinogen Could Be a Prognostic Marker of Renoprotective Effects of Alogliptin in Patients with Type 2 Diabetes.

Mizushige T, Kobori H, Nishijima Y, Yano Y, Sakata K, Hayakawa M, Nishiyama A - J Diabetes Res (2015)

ΔUrinary concentrations of Alb normalized by urinary concentrations of creatinine (UAlbCR) defined by the cutoff value of urinary concentrations of angiotensinogen normalized by urinary concentrations of creatinine (UAGTCR) before treatment. When all patients were redivided into two groups, those with higher UAGTCR levels before treatment (Group H, n = 20) and those with lower levels (Group L), ΔUAlbCR was significantly lower in Group H than in Group L (−46.3 ± 32.5 versus +12.2 ± 14.9 mg/g Cr, P = 0.0474).
© Copyright Policy - open-access
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC4562181&req=5

fig3: ΔUrinary concentrations of Alb normalized by urinary concentrations of creatinine (UAlbCR) defined by the cutoff value of urinary concentrations of angiotensinogen normalized by urinary concentrations of creatinine (UAGTCR) before treatment. When all patients were redivided into two groups, those with higher UAGTCR levels before treatment (Group H, n = 20) and those with lower levels (Group L), ΔUAlbCR was significantly lower in Group H than in Group L (−46.3 ± 32.5 versus +12.2 ± 14.9 mg/g Cr, P = 0.0474).
Mentions: Based on this cutoff value of UAGTCR (i.e., ≥20.8 μg/g Cr or <20.8 μg/g Cr), we divided all patients into 2 groups: higher (Group H, n = 20) and lower (Group L) values of UAGTCR at baseline. Clinical characteristics (Table 3) and baseline laboratory data (gender, age, BMI, treatment duration of T2D, HbA1c (NGSP), eGFR, SBP, DBP, and medications) (Table 4) were not significantly different between Group H and Group L. However, ΔUAlbCR was significantly lower in Group H than in Group L (−46.3 ± 32.5 versus +12.2 ± 14.9 mg/g Cr, P = 0.0474, Figure 3).

Bottom Line: Alogliptin treatment tended to decrease UAlbCR (99.6 ± 26.8 versus 114.6 ± 36.0 mg/g Cr, P = 0.198).When all patients were redivided into two groups, those with higher values of UAGTCR before the treatment (Group H, n = 20) and those with lower values (Group L), Group H showed significantly decreased UAlbCR in response to alogliptin (-14.6 ± 8.6 versus +22.8 ± 16.8%, P = 0.033).Urinary AGT could be a prognostic marker of renoprotective effects of alogliptin in patients with T2D.

View Article: PubMed Central - PubMed

Affiliation: Kagawa University School of Medicine, Kagawa 761-0793, Japan ; Jichi Medical University School of Medicine, Tochigi, Japan.

ABSTRACT

Background: The aims of this study were (1) to examine the renoprotective effects of alogliptin and (2) to establish urinary angiotensinogen (AGT) as a prognostic marker of renoprotective effects of alogliptin in patients with type 2 diabetes (T2D).

Methods: In 43 patients with T2D (18 women, 66.1 ± 1.71 years), 25 mg/day of alogliptin was added to the traditional hypoglycemic agents and/or nondrug treatments. Urinary concentrations of albumin (Alb) and AGT, normalized by urinary concentrations of creatinine (Cr) (UAlbCR and UAGTCR, respectively), were measured before and after the 12-week alogliptin treatment.

Results: Alogliptin treatment tended to decrease UAlbCR (99.6 ± 26.8 versus 114.6 ± 36.0 mg/g Cr, P = 0.198). Based on % change in UAlbCR, patients were divided into two groups, responders (< -25%) and nonresponders (≥ -25%), and a logistic analysis of UAGTCR before treatment showed cutoff value of 20.8 µg/g Cr. When all patients were redivided into two groups, those with higher values of UAGTCR before the treatment (Group H, n = 20) and those with lower values (Group L), Group H showed significantly decreased UAlbCR in response to alogliptin (-14.6 ± 8.6 versus +22.8 ± 16.8%, P = 0.033).

Conclusion: Urinary AGT could be a prognostic marker of renoprotective effects of alogliptin in patients with T2D.

No MeSH data available.


Related in: MedlinePlus